Table 1.

Characteristics of the included studies.

Study	Year	Design	Sample size	Schedule	Response rate	N% on ART	Mean CD4 count (cells/μl)
Fonseca et al. (18)	2005	RCT	192	a. 20 μg M0–1–6 b. 40 μg M0–1–6	a. 34.0% b. 46.9%	a+b. 86%	429
Launay et al. (20)	2011	RCT	286	a. 20 μg M0–1–6 b. 40 μg M0–1–2–6	a. 64.5% b. 82.1%	a. 86% b. 80%	a. 516 b. 509
Chaiklang et al. (21)	2013	RCT	132	a. 20 μg M0–1–6 b. 20 μg M0–1–2–6 c. 40 μg M0–1–2–6	a. 86.6% b. 93.2% c. 95.5%	a. 100% b. 100% c. 100%	a. 400 b. 544 c. 544
David Rey et al. (17)	2015	RCT	178	a. 20 μg M0–1–6 b. 40 μg M0–1–6	a. 67% b. 74%	a. 87% b. 86%	a. 254 b. 207
Rey et al. (22)	2000	Prospective	20	20 μg M0–1–2	55%	85%	470
Paitoonpong et al. (23)	2008	Prospective	28	20 μg M0–1–6	71.4%	100%	324
Ungulkraiwit et al. (24)	2007	Prospective	65	20 μg M0–1–6	46.2%	88%	345
Fuster et al. (25)	2016	Prospective	245	20 μg M0–1–6	62%	94.7%	406
Sasaki Md ( 26 ).	2003	RCT	40	40 μg M0–1–6	60%	99%	462
Cooper et al. (27)	2005	RCT	19	40 μg M0–1–2	89%	100%	NA
Pasricha et al. (28)	2006	Prospective	40	NA	82.5%	0	NA
Viega et al. (29)	2006	Prospective	47	NA	63.8%	91%	NA
Cornejo-Juarez et al. (30)	2006	Prospective	40	40 μg M0–1–6	60%	65%	225
Cruciani et al. (31)	2009	Prospective	65	40 μg M0–1–2	60%	80%	533
Overton et al. (32)	2010	RCT	23	40 μg M0–1–3	65.2%	77%	446
Potsch et al. (33)	2010	Prospective	47	40 μg M0–1–2–6	89%	79%	402
Potsch et al. (34)	2012	Prospective	163	40 μg M0–1–2–6	91%	80%	NA

ART, antiretroviral therapy; RCT, randomized controlled trial; M, month; NA, not assessed.